NASDAQ:BOLT Bolt Biotherapeutics Q3 2025 Earnings Results & Report $6.10 +0.19 (+3.23%) As of 11:55 AM Eastern This is a fair market value price provided by Massive. Learn more. Bolt Biotherapeutics beat analyst expectations on both earnings and revenue in its Q3 2025 results, released November 12, 2025. The company reported EPS of -$3.72 versus the -$5.07 consensus estimate, while revenue of $2.17 million topped the $821 thousand estimate by $1.35 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2025Report DateNovember 12, 2025TimeBefore Market OpensConference Call7:00 AM ET Bolt Biotherapeutics EPS ResultsActual EPS-$3.72Consensus EPS -$5.07Beat/MissBeat by +$1.35One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersBolt Biotherapeutics Revenue ResultsActual Revenue$2.17 millionExpected Revenue$821 thousandBeat/MissBeat by +$1.35 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Bolt Biotherapeutics Q3 2025 Earnings FAQ Did Bolt Biotherapeutics beat earnings estimates for Q3 2025? Bolt Biotherapeutics (NASDAQ:BOLT) reported earnings of -$3.72 per share for Q3 2025, beating the consensus estimate of -$5.07. The report was announced on Wednesday, November 12, 2025. What was Bolt Biotherapeutics' revenue for Q3 2025? Bolt Biotherapeutics reported revenue of $2.17 million for Q3 2025, against a consensus estimate of $821 thousand. Bolt Biotherapeutics Earnings HeadlinesBolt Biotherapeutics, Inc. (NASDAQ:BOLT) Stock Short Interest Report for OctoberNovember 13 at 1:41 AM | americanbankingnews.comBolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 12 at 4:05 PM | globenewswire.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 13 at 1:00 AM | Base Camp Trading (Ad)Bolt Biotherapeutics (BOLT) Expected to Announce Quarterly Earnings on WednesdayNovember 10 at 3:43 AM | americanbankingnews.comINVESTIGATION ALERT - The M&A Class Action Firm Is Investigating the Merger – RRC, SGRY, BOLT and PCRX - IS IT A FAIR DEAL FOR YOU?November 4, 2026 | globenewswire.comBolt Biotherapeutics to Participate in Upcoming ConferencesNovember 3, 2026 | globenewswire.comSee More Bolt Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bolt Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bolt Biotherapeutics and other key companies, straight to your email. Email Address About Bolt BiotherapeuticsBolt Biotherapeutics (NASDAQ:BOLT) is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response. The company has also pursued myeloid cell engager therapies designed to activate macrophages and other immune cells against cancer. Its development programs have included BDC-1001, an investigational HER2-targeted ISAC evaluated in patients with HER2-expressing solid tumors, and BDC-3042, an investigational myeloid engager intended for use in combination with other cancer immunotherapies. Bolt Biotherapeutics was founded in 2015 and is headquartered in Redwood City, California. Its programs have been evaluated through clinical studies involving patients with advanced solid tumors.View Bolt Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record Growth Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
